NeuBase Therapeutics, Inc.
NBSENASDAQHealthcare
$0.38
$-0.01(-1.56%)
Market Cap$1418101
P/E Ratio—
52W High$4.44
52W Low$0.36
NeuBase Therapeutics, Inc. (NBSE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NBSE · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 9, 2023EPS Actual
-$0.95
Est. -$1.82 · +47.8%
Revenue
—
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 9, 2023
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
NBSE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q1 FY2024 | Feb 13, 2024 | -$0.97 | — | — | — | — | — |
| ▲ Q4 FY2023 | Nov 9, 2023 | -$1.82 | -$0.95 | +47.8% | — | — | — |
| ▲ Q3 FY2023 | Aug 14, 2023 | -$1.80 | -$1.26 | +30.0% | — | — | — |
| ▼ Q2 FY2023 | May 11, 2023 | -$2.00 | -$2.40 | -20.0% | — | — | — |
| ▼ Q1 FY2023 | Feb 14, 2023 | -$2.20 | -$2.60 | -18.2% | — | — | — |
| ▲ Q4 FY2022 | Dec 21, 2022 | -$5.40 | -$4.80 | +11.1% | — | — | — |
| ▲ Q3 FY2022 | Aug 11, 2022 | -$6.00 | -$5.20 | +13.3% | — | — | — |
| ▼ Q2 FY2022 | May 12, 2022 | -$5.20 | -$6.00 | -15.4% | — | — | — |
Q1 FY2024
Feb 13, 2024
EPS Actual
—
EPS Est.
-$0.97
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 9, 2023Beat
EPS Actual
-$0.95
EPS Est.
-$1.82
EPS Surpr.
+47.8%
Revenue
—
Q3 FY2023
Aug 14, 2023Beat
EPS Actual
-$1.26
EPS Est.
-$1.80
EPS Surpr.
+30.0%
Revenue
—
Q2 FY2023
May 11, 2023Miss
EPS Actual
-$2.40
EPS Est.
-$2.00
EPS Surpr.
-20.0%
Revenue
—
Q1 FY2023
Feb 14, 2023Miss
EPS Actual
-$2.60
EPS Est.
-$2.20
EPS Surpr.
-18.2%
Revenue
—
Q4 FY2022
Dec 21, 2022Beat
EPS Actual
-$4.80
EPS Est.
-$5.40
EPS Surpr.
+11.1%
Revenue
—
Q3 FY2022
Aug 11, 2022Beat
EPS Actual
-$5.20
EPS Est.
-$6.00
EPS Surpr.
+13.3%
Revenue
—
Q2 FY2022
May 12, 2022Miss
EPS Actual
-$6.00
EPS Est.
-$5.20
EPS Surpr.
-15.4%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.57 | $1.57 | $1.57 | 1 |
| Q4 FY2023 | $-2.00 | $-2.00 | $-2.00 | 1 |
| Q3 FY2023 | $1.39 | $1.39 | $1.39 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2023 | Nov 9, 2023 | +47.8% | $0.71 | $0.71 | -0.42% |
| ▲ Q3 FY2023 | Aug 14, 2023 | +30.0% | $0.76 | $0.70 | -7.64% |
| ▼ Q2 FY2023 | May 11, 2023 | -20.0% | $3.80 | $4.12 | +8.42% |
| ▼ Q1 FY2023 | Feb 14, 2023 | -18.2% | $7.80 | $7.17 | -8.08% |
| ▲ Q4 FY2022 | Dec 21, 2022 | +11.1% | $3.80 | $4.00 | +5.26% |
| ▲ Q3 FY2022 | Aug 11, 2022 | +13.3% | $23.40 | $22.80 | -2.56% |
| ▼ Q2 FY2022 | May 12, 2022 | -15.4% | $18.00 | $18.80 | +4.44% |
| ▲ Q1 FY2022 | Feb 10, 2022 | +4.0% | $29.80 | $26.20 | -12.08% |
Q4 FY2023-0.42%
Report Date
Nov 9, 2023
EPS Beat/Miss
+47.8%
Price Before
$0.71
Price After
$0.71
Q3 FY2023-7.64%
Report Date
Aug 14, 2023
EPS Beat/Miss
+30.0%
Price Before
$0.76
Price After
$0.70
Q2 FY2023+8.42%
Report Date
May 11, 2023
EPS Beat/Miss
-20.0%
Price Before
$3.80
Price After
$4.12
Q1 FY2023-8.08%
Report Date
Feb 14, 2023
EPS Beat/Miss
-18.2%
Price Before
$7.80
Price After
$7.17
Q4 FY2022+5.26%
Report Date
Dec 21, 2022
EPS Beat/Miss
+11.1%
Price Before
$3.80
Price After
$4.00
Q3 FY2022-2.56%
Report Date
Aug 11, 2022
EPS Beat/Miss
+13.3%
Price Before
$23.40
Price After
$22.80
Q2 FY2022+4.44%
Report Date
May 12, 2022
EPS Beat/Miss
-15.4%
Price Before
$18.00
Price After
$18.80
Q1 FY2022-12.08%
Report Date
Feb 10, 2022
EPS Beat/Miss
+4.0%
Price Before
$29.80
Price After
$26.20
Avg Beat Reaction-3.49%
Avg Miss Reaction+1.59%
Beat Rate5 / 8 quarters
Largest Move-12.08% (Q1 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NBSE ends December
NeuBase Therapeutics, Inc. (NBSE) most recently reported earnings on November 9, 2023 for Q4 FY2023, posting EPS of $-0.95 — beating the analyst consensus of $-1.82 by +47.8%. NBSE has beaten EPS estimates for 2 consecutive quarters. The next NBSE earnings date is expected around September 1, 2026.
Each quarter, investors track NBSE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NBSE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NBSE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NBSE earnings · 5 questionsNeuBase Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. NBSE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NBSE historically reports after market close (AMC).
NBSE earnings datewhen is NBSE earningsNBSE next earnings datewhen does NBSE report earningsNBSE earnings calendar
▸ Source: FMP · NeuBase Therapeutics, Inc. SEC filings · US GAAP · NeuBase Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026